Educate Why Aduhelm Isn't a Miracle for Alzheimer's
August 2021
You'll hear controversy about Aduhelm (aducanumab), the first new med for Alzheimer's disease in almost 20 years.
It's a monoclonal antibody given as an IV infusion every 4 weeks.
Patients with Alzheimer's and their families are often looking for a glimmer of hope. But Aduhelm doesn't seem to be it.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote